The legionella testing market is expected to be worth US$ 355.1 million in 2024. Diseases caused by Legionella require intensive care and hospitalization as it is considered one of the public health concerns.
The need for legionella testing is projected to rise at a promising CAGR of 9.9% through 2034. The industry is projected to surpass US$ 910 million by 2034. The rise in prevalence of Legionella-related disorders and the surge in awareness about their preventive management is anticipated to drive growth of the market.
| Attributes | Details |
|---|---|
| Legionella Testing Market Value for 2024 | US$ 355.1 million |
| Legionella Testing Market Value for 2034 | US$ 910 million |
| Legionella Testing Market Forecast CAGR for 2024 to 2034 | 9.9% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
| Historical CAGR | 12.4% |
|---|---|
| Forecast CAGR | 9.9% |
The historical CAGR of the Legionella testing market was 12.4%, indicating an impressive rate over the past few years. The forecast CAGR is expected to be 9.9%, indicating a steady decrease in the growth rate through 2034.
The forecast CAGR of 9.9% indicates a decrease in the growth rate of the market in comparison to the historical CAGR in the future. The fall in CAGR can be attributed to several factors, including
Principal Consultant
The table analyses the top five countries ranked by revenue, with South Korea holding the top position.
Due to government initiatives and technological advancements, South Korea is considered a prominent market. Stringent regulations and proactive measures to improve public health have spurred widespread adoption of Legionella testing in various facilities.
South Korea is a hub for technological innovation, which has led to the development of advanced testing methods and solutions. It is positioning it itself to be a leader in Legionella risk management.
The Forecast CAGRs from 2024 to 2034
| Countries | CAGR |
|---|---|
| United States | 10.1% |
| United Kingdom | 11.1% |
| China | 10.5% |
| Japan | 11.4% |
| South Korea | 12% |
The industry in the United States is heavily utilized due to stringent regulatory requirements imposed by federal and state agencies. Regulations mandate that Legionella testing be done in various facilities, such as healthcare facilities, hotels, and industrial sites, to ensure public health and safety.
Due to the relatively high incidence of Legionnaires disease, the industry is heavily utilized in the United Kingdom. The surge in awareness and proactive testing measures are taken to prevent future outbreaks in the country.
Large-scale infrastructure projects, industrial facilities, and high-rise structures are expanding due to the growth in industrialization and urbanization of the country.
The primary purpose is to reduce the possibility of Legionella contamination in such environments, where dense populations and intricate water systems encourage bacterial growth.
The aging infrastructure and burgeoning geriatric population in Japan have raised worries over public health and safety.
To ensure public health and safety, the industry widely mitigates the danger of Legionella contamination in public water systems, healthcare facilities, and older buildings.
Government initiatives to improve public health and safety have prompted the adoption of Legionella testing measures.
The focus on technological advancements and innovation has led to the development of advanced testing methods and solutions, thus driving growth in the industry.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The below section shows the leading segment. Based on type, the urine antigen testing (UAT) segment is registered to expand at 9.7% CAGR by 2034. Based on end-user, the clinical laboratories segment is registered to rise at 9.5% CAGR by 2034.
UAT provides quick, non-invasive results without requiring invasive procedures or specialist equipment for rapid detecteion of Legionella antigens in urine samples.
The rise in demand for diagnostic services is driven by factors such as population growth, aging demographics, and the rising prevalence of chronic diseases.
| Category | CAGR from 2024 to 2034 |
|---|---|
| Urine Antigen Testing (UAT) | 9.7% |
| Clinical Laboratories | 9.5% |
The urine antigen testing (UAT) segment is projected to expand at a CAGR of 9.7% by 2034, driven by its effectiveness and convenience in diagnosing ligionnaires disease.
UAT is becoming more popular as it offers rapid results and high sensitivity in detecting Legionella antigens in urine samples, where adoption is increasing, particularly in clinical settings and timely diagnosis is crucial for patient management.
Based on end-use, the clinical laboratories market expanded at 9.5% CAGR. There is a boost in demand for clinical laboratories diagnostic services, inclusive of Legionella antigen urine testing.
Clinical laboratories play a critical role in healthcare delivery by offering precise and dependable diagnostic tests, improving patient outcomes, and managing diseases.
Growth in the market is expected as urine antigen testing services are in constant demand from clinical laboratories due to the surge in frequency of Ligionnaires' disease.
Innovative entrepreneurs have used technological breakthroughs to challenge existing players of traditional testing methods in the highly competitive market sector inside the startup ecosystem.
The firms are introducing new testing solutions, like IoT-enabled monitoring devices, AI-powered analytics platforms, and quick testing kits. By providing affordable, user-friendly, and scalable solutions, they have challenged established players and gained traction with industrial sites, healthcare facilities, and other end customers.
Startups prioritizing agility, innovation, and customer-centricity are changing the market and raising competition, certainly leading to better risk management techniques and public health results.
Key developments in the Legionella Testing industry
| Attributes | Details |
|---|---|
| Estimated Market Size in 2024 | US$ 355.1 million |
| Projected Market Valuation in 2034 | US$ 910 million |
| Value-based CAGR 2024 to 2034 | 9.9% |
| Forecast Period | 2024 to 2034 |
| Historical Data Available for | 2019 to 2023 |
| Market Analysis | Value in US$ million |
| Key Regions Covered |
|
| Key Market Segments Covered |
|
| Key Countries Profiled |
|
| Key Companies Profiled |
|
As of 2024, the market for Legionella testing is expected to be valued at US$ 355.1 million.
The Legionella testing market is projected to expand at a CAGR of 9.9 % between 2024 and 2034.
The urine antigen testing (UAT) segment is projected to dominate the industry.
By 2034, the market value of Legionella testing is expected to reach US$ 910 million.
South Korea is likely the top-performing market, with a CAGR of 12%.
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2019 to 2023 and Forecast, 2024 to 2034
4.1. Historical Market Size Value (US$ Million) Analysis, 2019 to 2023
4.2. Current and Future Market Size Value (US$ Million) Projections, 2024 to 2034
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Type
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Type, 2019 to 2023
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Type, 2024 to 2034
5.3.1. Culture Media
5.3.2. Urine Antigen Testing (UAT)
5.3.3. Polymerase Chain Reaction (PCR)
5.3.4. Serology
5.3.5. Direct Fluorescent Antibody (DFA) Test
5.4. Y-o-Y Growth Trend Analysis By Type, 2019 to 2023
5.5. Absolute $ Opportunity Analysis By Type, 2024 to 2034
6. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By End-User
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By End-User, 2019 to 2023
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End-User, 2024 to 2034
6.3.1. Hospitals & Clinics
6.3.2. Clinical Laboratories
6.3.3. Others
6.4. Y-o-Y Growth Trend Analysis By End-User, 2019 to 2023
6.5. Absolute $ Opportunity Analysis By End-User, 2024 to 2034
7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Region
7.1. Introduction
7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2019 to 2023
7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2024 to 2034
7.3.1. North America
7.3.2. Latin America
7.3.3. Western Europe
7.3.4. Eastern Europe
7.3.5. South Asia and Pacific
7.3.6. East Asia
7.3.7. Middle East and Africa
7.4. Market Attractiveness Analysis By Region
8. North America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023
8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034
8.2.1. By Country
8.2.1.1. USA
8.2.1.2. Canada
8.2.2. By Type
8.2.3. By End-User
8.3. Market Attractiveness Analysis
8.3.1. By Country
8.3.2. By Type
8.3.3. By End-User
8.4. Key Takeaways
9. Latin America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034
9.2.1. By Country
9.2.1.1. Brazil
9.2.1.2. Mexico
9.2.1.3. Rest of Latin America
9.2.2. By Type
9.2.3. By End-User
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Type
9.3.3. By End-User
9.4. Key Takeaways
10. Western Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034
10.2.1. By Country
10.2.1.1. Germany
10.2.1.2. UK
10.2.1.3. France
10.2.1.4. Spain
10.2.1.5. Italy
10.2.1.6. Rest of Western Europe
10.2.2. By Type
10.2.3. By End-User
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Type
10.3.3. By End-User
10.4. Key Takeaways
11. Eastern Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034
11.2.1. By Country
11.2.1.1. Poland
11.2.1.2. Russia
11.2.1.3. Czech Republic
11.2.1.4. Romania
11.2.1.5. Rest of Eastern Europe
11.2.2. By Type
11.2.3. By End-User
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Type
11.3.3. By End-User
11.4. Key Takeaways
12. South Asia and Pacific Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034
12.2.1. By Country
12.2.1.1. India
12.2.1.2. Bangladesh
12.2.1.3. Australia
12.2.1.4. New Zealand
12.2.1.5. Rest of South Asia and Pacific
12.2.2. By Type
12.2.3. By End-User
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Type
12.3.3. By End-User
12.4. Key Takeaways
13. East Asia Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034
13.2.1. By Country
13.2.1.1. China
13.2.1.2. Japan
13.2.1.3. South Korea
13.2.2. By Type
13.2.3. By End-User
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Type
13.3.3. By End-User
13.4. Key Takeaways
14. Middle East and Africa Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023
14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034
14.2.1. By Country
14.2.1.1. GCC Countries
14.2.1.2. South Africa
14.2.1.3. Israel
14.2.1.4. Rest of MEA
14.2.2. By Type
14.2.3. By End-User
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Type
14.3.3. By End-User
14.4. Key Takeaways
15. Key Countries Market Analysis
15.1. USA
15.1.1. Market Share Analysis, 2023
15.1.1.1. By Type
15.1.1.2. By End-User
15.2. Canada
15.2.1. Market Share Analysis, 2023
15.2.1.1. By Type
15.2.1.2. By End-User
15.3. Brazil
15.3.1. Market Share Analysis, 2023
15.3.1.1. By Type
15.3.1.2. By End-User
15.4. Mexico
15.4.1. Market Share Analysis, 2023
15.4.1.1. By Type
15.4.1.2. By End-User
15.5. Germany
15.5.1. Market Share Analysis, 2023
15.5.1.1. By Type
15.5.1.2. By End-User
15.6. UK
15.6.1. Market Share Analysis, 2023
15.6.1.1. By Type
15.6.1.2. By End-User
15.7. France
15.7.1. Market Share Analysis, 2023
15.7.1.1. By Type
15.7.1.2. By End-User
15.8. Spain
15.8.1. Market Share Analysis, 2023
15.8.1.1. By Type
15.8.1.2. By End-User
15.9. Italy
15.9.1. Market Share Analysis, 2023
15.9.1.1. By Type
15.9.1.2. By End-User
15.10. Poland
15.10.1. Market Share Analysis, 2023
15.10.1.1. By Type
15.10.1.2. By End-User
15.11. Russia
15.11.1. Market Share Analysis, 2023
15.11.1.1. By Type
15.11.1.2. By End-User
15.12. Czech Republic
15.12.1. Market Share Analysis, 2023
15.12.1.1. By Type
15.12.1.2. By End-User
15.13. Romania
15.13.1. Market Share Analysis, 2023
15.13.1.1. By Type
15.13.1.2. By End-User
15.14. India
15.14.1. Market Share Analysis, 2023
15.14.1.1. By Type
15.14.1.2. By End-User
15.15. Bangladesh
15.15.1. Market Share Analysis, 2023
15.15.1.1. By Type
15.15.1.2. By End-User
15.16. Australia
15.16.1. Market Share Analysis, 2023
15.16.1.1. By Type
15.16.1.2. By End-User
15.17. New Zealand
15.17.1. Market Share Analysis, 2023
15.17.1.1. By Type
15.17.1.2. By End-User
15.18. China
15.18.1. Market Share Analysis, 2023
15.18.1.1. By Type
15.18.1.2. By End-User
15.19. Japan
15.19.1. Market Share Analysis, 2023
15.19.1.1. By Type
15.19.1.2. By End-User
15.20. South Korea
15.20.1. Market Share Analysis, 2023
15.20.1.1. By Type
15.20.1.2. By End-User
15.21. GCC Countries
15.21.1. Market Share Analysis, 2023
15.21.1.1. By Type
15.21.1.2. By End-User
15.22. South Africa
15.22.1. Market Share Analysis, 2023
15.22.1.1. By Type
15.22.1.2. By End-User
15.23. Israel
15.23.1. Market Share Analysis, 2023
15.23.1.1. By Type
15.23.1.2. By End-User
16. Market Structure Analysis
16.1. Competition Dashboard
16.2. Competition Benchmarking
16.3. Market Share Analysis of Top Players
16.3.1. By Regional
16.3.2. By Type
16.3.3. By End-User
17. Competition Analysis
17.1. Competition Deep Dive
17.1.1. Quidel Corporation
17.1.1.1. Overview
17.1.1.2. Product Portfolio
17.1.1.3. Profitability by Market Segments
17.1.1.4. Sales Footprint
17.1.1.5. Strategy Overview
17.1.1.5.1. Marketing Strategy
17.1.2. Abbott (Alere)
17.1.2.1. Overview
17.1.2.2. Product Portfolio
17.1.2.3. Profitability by Market Segments
17.1.2.4. Sales Footprint
17.1.2.5. Strategy Overview
17.1.2.5.1. Marketing Strategy
17.1.3. Merck KGaA
17.1.3.1. Overview
17.1.3.2. Product Portfolio
17.1.3.3. Profitability by Market Segments
17.1.3.4. Sales Footprint
17.1.3.5. Strategy Overview
17.1.3.5.1. Marketing Strategy
17.1.4. Bio-Rad Laboratories, Inc.
17.1.4.1. Overview
17.1.4.2. Product Portfolio
17.1.4.3. Profitability by Market Segments
17.1.4.4. Sales Footprint
17.1.4.5. Strategy Overview
17.1.4.5.1. Marketing Strategy
17.1.5. Thermo Fisher Scientific Inc.
17.1.5.1. Overview
17.1.5.2. Product Portfolio
17.1.5.3. Profitability by Market Segments
17.1.5.4. Sales Footprint
17.1.5.5. Strategy Overview
17.1.5.5.1. Marketing Strategy
17.1.6. Pro-lab Diagnostics, Inc.
17.1.6.1. Overview
17.1.6.2. Product Portfolio
17.1.6.3. Profitability by Market Segments
17.1.6.4. Sales Footprint
17.1.6.5. Strategy Overview
17.1.6.5.1. Marketing Strategy
17.1.7. bioMérieux
17.1.7.1. Overview
17.1.7.2. Product Portfolio
17.1.7.3. Profitability by Market Segments
17.1.7.4. Sales Footprint
17.1.7.5. Strategy Overview
17.1.7.5.1. Marketing Strategy
17.1.8. IDEXX Corporation
17.1.8.1. Overview
17.1.8.2. Product Portfolio
17.1.8.3. Profitability by Market Segments
17.1.8.4. Sales Footprint
17.1.8.5. Strategy Overview
17.1.8.5.1. Marketing Strategy
17.1.9. Eurofins Scientific
17.1.9.1. Overview
17.1.9.2. Product Portfolio
17.1.9.3. Profitability by Market Segments
17.1.9.4. Sales Footprint
17.1.9.5. Strategy Overview
17.1.9.5.1. Marketing Strategy
17.1.10. Beckman Coulter, Inc.
17.1.10.1. Overview
17.1.10.2. Product Portfolio
17.1.10.3. Profitability by Market Segments
17.1.10.4. Sales Footprint
17.1.10.5. Strategy Overview
17.1.10.5.1. Marketing Strategy
18. Assumptions & Acronyms Used
19. Research Methodology
Explore Healthcare Insights
View Reports
Legionella Testing Market
